Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ibrutinib/Rituximab Effective, Safe as Frontline Treatment for Older Patients With MCL

Publish date:: August 12, 2019

Key clinical point: Ibrutinib/rituximab is an effective frontline therapy for older patients with mantle cell lymphoma (MCL).

Major finding: The objective response rate for 41 evaluable patients was 93%.

Study details: A phase 2 trial with 48 transplant-ineligible patients age 65 years and older with newly diagnosed MCL.

Disclosures: The National Cancer Institute supported the study. Dr. Jain reported having no financial disclosures.

Citation:

Jain P et al. 15-ICML, Abstract 011.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in B Cell Lymphoma

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma,

Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,